http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Immunotherapy for NSCLC - addressing heterogeneity to improve clinical outcomes
( Darren Wan-teck Lim ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Immunotherapy with checkpoint inhibitors has firmly entrenched itself as standard of care practice in NSCLC where EGFR/ALK testing is negative. Yet even within this group, heterogeneity exists, and the relative activity of immunotherapy in oncogene driven lung cancer is still not well defined. Even within EGFR/ALK positive NSCLC, there could exist subsets where immunotherapy may be useful. Recent updates from immunotherapy studies that address heterogeneity, and potential new approaches will be discussed.
Is it time for a paradigm shift in first line treatment of EGFR mutant NSCLC?
( Darren Wan-teck Lim ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
EGFR mutant NSCLC represents the majority of lung cancer in Asia. All generations of EGFR tyrosine kinase inhibitors have demonstrated excellent efficacy in advanced disease. Osimertinib was developed specifically to address T790M mutation, the dominant resistance mechanism following failure of 1st/2nd generation inhibitors. Moving the use of osimertinib to the first-line setting represents a paradigm shift in management of EGFR mt lung cancer, as it challenges current practice of sequencing EGFR inhibitors. The discussion will focus on recent overall survival data from FLAURA and its possible impact on existing practice in EGFR mutant NSCLC in Asia.